BIOCAD announced plans to enter the EU market

11.11.2019

BIOCAD announced plans to enter the EU market

Frankfurt, CPhI-2019 became the first large-scale international platform to present the BIOCAD's latest original drugs based on monoclonal antibodies - netakimab and progolimab; plans were also announced for their entry to the European market

More Category: Media release
Vietnam gives green light to cancer treatment drugs from Russia

09.10.2019

Vietnam gives green light to cancer treatment drugs from Russia

The preparations of the Russian biotechnological company Biocad are becoming increasingly popular in the global pharmaceutical market. To create a new drug, the company's specialists go through a long process: from molecular search to mass production. The company's medicines are used to treat cancer and autoimmune diseases.

More Category: Media release
Biocad received a clinical trial authorization for its original medicinal product in the EU

09.10.2019

Biocad received a clinical trial authorization for its original medicinal product in the EU

Biocad received a clinical trial authorization for its original medicinal product in the EU. The company starts the clinical trial “DOMAJOR” in Slovakia of the drug prolgolimab in treatment of non small cell lung cancer. The company intends to invest over 25 million euro in this clinical development and launch the product in China and the EU.

More Category: News
BIOCAD and Shanghai Pharma Holding finalized the deal to establish a joint venture in China

26.09.2019

BIOCAD and Shanghai Pharma Holding finalized the deal to establish a joint venture in China

On September the 17th, during a ceremony in Constantine’s Palace, Russian Prime Minister Dmitry Medvedev and Premier of the State Council of the People’s Republic of China Li Keqiang witnessed the signing of final agreement between BIOCAD and Shanghai Pharma Holding to establish a joint venture between the two high-visibility players in order to bring more advanced biological products to China.

More Category: Media release
Biocad received a clinical trial authorization for its original medicinal product in the EU

25.09.2019

Biocad received a clinical trial authorization for its original medicinal product in the EU

Biotechnology company Biocad received a clinical trial authorization for its original medicinal product in the EU. The company starts the clinical trial “DOMAJOR” in Slovakia of the drug prolgolimab in treatment of non small cell lung cancer. The company intends to invest over 25 million euro in this clinical development and launch the product in China and the EU.

More Category: News